目的研究MRI联合肿瘤标志物 对直肠癌患者术前TNM分期诊断的临床价 值。方法 选择我院2015年12月到2017年 12月直肠癌患者共200例，所有患者采用 MRI检测并检测血清中癌胚抗原(CEA)及 糖类抗原(CA19-9)水平。结果 随着肿瘤 分期增加，CEA、CA19-9水平也逐渐增 加，组间差异有统计学意义(P＜0.05)； 与金标准比较，MRI检测T分期总准确率 为83.00%，MRI联合肿瘤标志物T分期总 准确率为90.00%，差异有统计学意义 (F=4.196，P=0.041)；与金标准比较， MRI检测对N分期总准确率为74.50%，MRI 联合肿瘤标志物检测N分期总准确率为 83.50%，差异有统计学意义(F=4.883， P=0.027)。结论 MRI联合肿瘤标志物对直 肠癌患者术前分期准确率较高。

Objective To study the clinical value of MRI combined with tumor markers in preoperative TNM staging of patients with rectal cancer. Methods A total of 200 patients with rectal cancer from December 2015 to December 2017 in the hospital were selected. All patients were detected by MRI, and the serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9) levels were measured. Results With the increase of tumor stage, the levels of CEA and CA19-9 were also gradually increased (P<0.05). Compared with the gold standard, the total accuracy rate in detecting T stage was 83.00% by MRI and was 90.00% by MRI combined with tumor markers (F=4.196, P=0.041). Compared with the gold standard, the total accuracy rate in the detection for N stage was 74.50% by MRI and was 83.50% by MRI combined with tumor markers (F=4.883, P=0.027). Conclusion MRI combined with tumor markers has high accuracy of preoperative staging in patients with rectal cancer.